- Home
- ME
as 07-26-2024 4:00pm EST
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 198.1M | IPO Year: | N/A |
| Target Price: | $0.47 | AVG Volume (30 days): | 4.5M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.35 - $1.95 | Next Earning Date: | 08-06-2024 |
| Revenue: | $219,638,000 | Revenue Growth: | -26.66% |
| Revenue Growth (this year): | 10.73% | Revenue Growth (next year): | 16.95% |
Stock Insider Trading Activity of 23andMe Holding Co. (ME)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HIBBS KATHY L | ME | Chief Administrative Officer | May 2 '24 | Sell | $0.49 | 38,551 | $19,048.05 | 1,252,315 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Apr 18 '24 | Sell | $0.47 | 38,548 | $18,148.40 | 1,252,315 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Apr 4 '24 | Sell | $0.50 | 38,548 | $19,281.71 | 1,252,315 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Mar 21 '24 | Sell | $0.46 | 38,548 | $17,893.98 | 1,252,315 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Mar 7 '24 | Sell | $0.53 | 38,548 | $20,430.44 | 1,252,315 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Feb 22 '24 | Sell | $0.61 | 38,548 | $23,325.39 | 1,239,827 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Feb 15 '24 | Sell | $0.78 | 38,548 | $30,210.07 | 1,280,349 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Jan 25 '24 | Sell | $0.73 | 38,548 | $27,997.41 | 1,280,349 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Jan 11 '24 | Sell | $0.72 | 38,548 | $27,581.09 | 1,280,349 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Dec 28 '23 | Sell | $0.93 | 38,548 | $35,903.61 | 1,280,349 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Dec 14 '23 | Sell | $0.97 | 38,548 | $37,221.95 | 1,280,349 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Nov 30 '23 | Sell | $0.88 | 38,548 | $33,752.63 | 1,280,349 | SEC Form 4 |
| HIBBS KATHY L | ME | Chief Administrative Officer | Nov 2 '23 | Sell | $0.87 | 38,548 | $33,436.54 | 1,284,976 | SEC Form 4 |
Latest 23andMe Holding Co. News
ME Breaking Stock News: Dive into ME Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
23andMe to Report Q1 FY2025 Financial Results
GlobeNewswire
2 days ago
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
Medical Device Network
25 days ago
23andMe and Nightingale partner to pilot blood-based risk detection panel
MT Newswires
a month ago
23andMe to Offer Free Blood Testing for Members in Pilot Program
GlobeNewswire
a month ago
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
MT Newswires
2 months ago
Update: 23andMe Under Scrutiny by UK, Canadian Privacy Regulators Over October Data Breach
MT Newswires
2 months ago
23andMe Under Scrutiny by UK, Canadian Privacy Regulators Over October 2023 Data Breach
Motley Fool
2 months ago
BigBear.ai Stock: Buy, Sell, or Hold?
Compare ME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ME 23andMe Holding Co. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.